Comparison of prevalence and management of left atrial appendage thrombi under old and new anticoagulants prior to left atrial catheter ablation

Costa, Antoine Da; Delolme, Clarisse; Guichard, Jean-Baptiste; Gerbay, Antoine; Pierrard, Romain; Romeyer‐Bouchard, Cécile; Isaaz, Karl

doi:10.1016/j.ahj.2017.07.016

Cited by 19 publications

(16 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies showed that the presence of LA/LAA thrombi increases significantly with higher CHADS 2 scores despite appropriate anticoagulation with warfarin [19, 20]. In the era of NOACs, similar results have also been reported [18, 21]. In our analysis, the LVEF was independently associated with LA thrombi.…”

Section: Discussionsupporting

confidence: 87%

The incidence of left atrial appendage thrombi on transesophageal echocardiography after pretreatment with apixaban for cardioversion in the real-world practice

et al. 2018

View full text Add to dashboard Cite

The risk of thromboembolisms during the post-cardioversion period is high. For patients with persistent atrial fibrillation (AF), anticoagulation with warfarin (INR 2.0~3.0) is recommended for at least three weeks prior and four weeks after cardioversion. We aimed to evaluate the efficacy of apixaban in preventing thromboembolic events during post-cardioversion. We enrolled 127 consecutive persistent AF patients (83 persistent, 44 longstanding persistent AF), scheduled to undergo cardioversion and were pretreated with apixaban. All patients underwent transesophageal echocardiography (TEE) to rule out thrombi in the left atrium (LA) or LA appendage (LAA) after anticoagulation with apixaban. The median duration of anticoagulation before the TEE was 37 (interquartile range [IQR] 34, 50) days. There were 7 patients (5.5%) with visible thrombi in the LAA. A spontaneous echo contrast was noted in 24 (18.9%) patients. Cardioversion was attempted in 117 patients, and they were prescribed amiodarone before the elective DC cardioversion. Sinus rhythm was achieved in 37 patients (31.6%) by amiodarone itself. DC cardioversion was attempted in 80 patients and was successful in 73 (91.3%). None of the cardioverted patients had any thromboembolic events within one month. Transient ischemic attacks were observed in one patient during a median follow up period of 202 days (IQR 143, 294). In conclusion, apixaban could be used as an anticoagulant for patients scheduled for cardioversion. However, the incidence of thrombi was not negligible. TEE or other imaging modalities should be considered before cardioversion or other invasive procedures.

show abstract

Section: Discussionsupporting

confidence: 87%

The incidence of left atrial appendage thrombi on transesophageal echocardiography after pretreatment with apixaban for cardioversion in the real-world practice

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Several recent studies have reported the percentage of LAT on TEE ranging from 2.1% to 4.4% in AF patients on DOACs before catheter ablation. [19][20][21][22][23] There was no difference in the prevalence of LAT between patients with DOACs and those with warfarin. 19,20 Mitamura et al 22 identified 4% LAT in persistent AF patients on dabigatran undergoing electrical cardioversion.…”

Section: Prevalence Of Lat In Af Patients On Doacsmentioning

confidence: 99%

“…In the present study, the rate of LAT was 4.4% in AF patients on DOACs, almost similar to or even higher than the rate in the prior reports. [19][20][21][22][23] In the previous studies, DOACs were not evenly distributed, likely stemming from the later introduction of apixaban and edoxaban for clinical use compared with dabigatran and rivaroxaban during the study period. However, in the present study, the 4 DOACs were evenly distributed, and the number of patients on apixaban treatment with LAT was relatively higher.…”

Section: Prevalence Of Lat In Af Patients On Doacsmentioning

confidence: 99%

Left Atrial Appendage Thrombus Prior to Atrial Fibrillation Ablation in the Era of Direct Oral Anticoagulants

Harada

Koshikawa

Motoike

et al. 2018

Circ J

View full text Add to dashboard Cite

show abstract

“…Обсервационная работа D.Frenkel et al, напротив, не показала статистически значимой разницы терапии варфарином или НОАК в отношении профилактики тромбоза УЛП у пациентов с ФП (2,9% против 4,4%, р=0,45) [41]. Достоверных различий в частоте выявления тромбоза УЛП на фоне терапии варфарином либо НОАК не представлено и в публикации A.D.Da Costa et al [42]. Среди 576 пациентов, включенных в исследование, тромб в полости ушка был обнаружен у 5 больных (2,6%), принимавших варфарин, и у 8 больных (2,1%), находившихся на терапии НОАК.…”

Section: антикоагулянтная терапия и тромбоз ушка левого предсердияunclassified

Left atrial appendage thrombosis in atrial fibrillation - current status of the problem

Кривошеев¹,

Башта

Красильникова

et al. 2020

Vestnik aritmologii

View full text Add to dashboard Cite

show abstract

Comparison of prevalence and management of left atrial appendage thrombi under old and new anticoagulants prior to left atrial catheter ablation

Cited by 19 publications

References 31 publications

The incidence of left atrial appendage thrombi on transesophageal echocardiography after pretreatment with apixaban for cardioversion in the real-world practice

The incidence of left atrial appendage thrombi on transesophageal echocardiography after pretreatment with apixaban for cardioversion in the real-world practice

Left Atrial Appendage Thrombus Prior to Atrial Fibrillation Ablation in the Era of Direct Oral Anticoagulants

Left atrial appendage thrombosis in atrial fibrillation - current status of the problem

Contact Info

Product

Resources

About